image dons

I make a donation

ALBION

Evaluate the impact of increasing the loading dose of clopidogrel on the platelet inhibition and the peri-procedural infarcts in patients presenting an acute coronary syndrome

Terminée

La Grande Journée du Coeur (13 juin 2023)
Attention : plus que quelques places restantes !

La Grande Journée du Coeur (mardi 13 juin 2023)
Les présentations sont en ligne

Colloquium "Rythme et conduction" (23 avril 2024)
Inscrivez-vous !

logo étude

objectif

Increase the loading dose of clopidogrel (Plavix®) on the platelet inhibition and the peri-procedural infarcts in patients with acute coronary syndromes.

date de réalisation

2006

nombre de patients

103

nombre de centres participants

7 french centers

type de financement

Private (Sanofi-Aventis)

Référence

NCT00360386

Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis (ALBION)

Study Description
  • To compare the Kinetics of inhibition of platelet aggregation (aggregometry) and platelet activation (flow cytometry) with different loading doses of clopidogrel ;
  • To evaluate the effect on various parameters of inflammation and necrosis and the safety of these loading doses.

source clinicaltrials.gov

Publications

  • Slow response to clopidogrel predicts low response
    Anne Bellemain-Appaix, Gilles Montalescot, Johanne Silvain, Olivier Barthélémy, Farzin Beygui, Jean-Philippe Collet, Georges Sideris, Catherine Meuleman, Claire Bal-Dit-Sollier, Nicolas Lellouche, Grégory Ducrocq, Michel Slama, Olivier Milleron, Patrick Henry, Ludovic Drouet, ALBION Investigators
    Publicated in Journal of the American College of Cardiology
  • A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial
    Gilles Montalescot, Georges Sideris, Catherine Meuleman, Claire Bal-dit-Sollier, Nicolas Lellouche, Ph Gabriel Steg, Michel Slama, Olivier Milleron, Jean-Philippe Collet, Patrick Henry, Farzin Beygui, Ludovic Drouet, ALBION Trial Investigators
    Publicated in Journal of the American College of Cardiology

Autres études

+

ACORES-2

En cours


Evaluate the effect of RAS blockers discontinuation versus continuation on clinical course of patients infected with COVID-19.
+

BIO-TAVI

En cours


Correlation between the platelet reactivity, the von Willebrand factor and bleeding and thrombotic events occuring during the year following TAVI
+

ABYSS

En cours


Phase 4 trial, evaluating the interest of betablocking treatment in the long term treatment of non-complicated myocardial infarct.